News
Apricity Fertility unveils innovative egg sharing programme
In response to the growing need for accessible fertility treatments and the urgent demand for egg donors in the UK, Apricity Fertility has introduced a new initiative – Egg Sharing.
Against a backdrop of the cost of living crisis and NHS criteria this programme aims to make IVF more affordable, while simultaneously addressing the nationwide shortage of donor eggs.
Meeting the Need for Affordable IVF Solutions
As more women and families turn to IVF to start or expand their families, the financial burden of treatment continues to be a significant barrier. The costs associated with IVF can often make it inaccessible to many who need it. Recognising this, Apricity’s Egg Sharing programme offers a creative solution. By participating in egg sharing, couples and women can reduce their treatment costs, making the journey to parenthood more attainable. This approach not only eases the financial strain but also provides an invaluable resource for those in need of donor eggs.
Same-Sex Female Couples and Barriers to NHS Care
For many same-sex female couples, accessing fertility treatment on the NHS can be challenging due to restrictive eligibility criteria. Apricity’s Egg Sharing Programme offers a unique solution for couples who may not qualify for NHS funding. By sharing your eggs, you can make fertility treatment more affordable, while also supporting another family who relies on donor eggs to start their own journey. This creates a supportive community, where your contribution helps others overcome their fertility challenges.
Tackling the Egg Donor Shortage Head-On
The UK’s fertility sector has long been challenged by a scarcity of egg donors, leading to extended waiting periods for hopeful parents. Apricity’s Egg Sharing programme is designed to alleviate this issue. By offering egg sharing, this initiative ensures that more eggs are available to individuals and couples facing fertility challenges, thereby helping them achieve their dream of parenthood sooner.
“We are thrilled to launch our Egg Sharing programme, a significant step forward in our mission to breaking down the barriers to accessing fertility care,” said Mel Chacksfield, CEO of Apricity Fertility.
“This service not only makes IVF more accessible and affordable for many women but also strengthens our ability to support families who rely on egg donation. Our ongoing commitment to personalised care and innovation in the fertility sector continues to drive us to meet the diverse needs of our patients.”
How it Works
Women interested in participating in the Egg Sharing programme must meet certain eligibility criteria, including age, BMI, and ovarian reserve. Comprehensive counselling is provided throughout the process, ensuring participants are fully informed and supported. During the IVF process, a portion of the retrieved eggs is used for the participant’s own treatment, while the remaining eggs are donated to Apricity’s frozen egg bank. This unique arrangement not only reduces the financial burden on participants but also provides a critical resource for others in need of donor eggs.
For more details on the Egg Sharing programme, please visit Apricity’s website.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Pregnancy
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur6 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health







2 Comments